These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874 [TBL] [Abstract][Full Text] [Related]
3. Clinical inquiries. What is the best initial treatment of Parkinson's disease? Schreck J; Kelsberg G; Rich J; Ward R J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387 [No Abstract] [Full Text] [Related]
4. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Van Gerpen JA; Ahlskog JE Neurology; 2001 Jul; 57(2):368-9; author reply 369-70. PubMed ID: 11468339 [No Abstract] [Full Text] [Related]
5. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Ben-Shlomo Y; Lees A; Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425 [No Abstract] [Full Text] [Related]
6. Deprenyl in Parkinson's disease. Korczyn AD; Nisipeanu P Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617 [No Abstract] [Full Text] [Related]
7. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Olanow CW; Mytilineou C; Tatton W Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720 [No Abstract] [Full Text] [Related]
8. Selegiline in Parkinson's disease. Calne DB BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790 [No Abstract] [Full Text] [Related]
9. Deprenyl as symptomatic therapy in Parkinson's disease. Golbe LI Clin Neuropharmacol; 1988 Oct; 11(5):387-400. PubMed ID: 3146432 [No Abstract] [Full Text] [Related]
10. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
11. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis]. Mil'chakova AE; Popov GR; Bykov AV; Gekht AB Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194 [No Abstract] [Full Text] [Related]
18. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related]
19. [Cost-effect pharmacological studies of Parkinson's disease]. Chikina ES; Belousov IuB Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):68-72. PubMed ID: 16329642 [No Abstract] [Full Text] [Related]
20. Retention rate of selegiline in early Parkinson's disease: a retrospective survey. Keränen T; Mattila T; Luukkaala T; Kuusisto H Int J Clin Pract; 2012 Oct; 66(10):1014. PubMed ID: 22994335 [No Abstract] [Full Text] [Related] [Next] [New Search]